Skip to main content

Table 1 Demographic characteristics (total vaccinated cohort)

From: Safety and immunogenicity of a varicella vaccine without human serum albumin (HSA) versus a HSA-containing formulation administered in the second year of life: a phase III, double-blind, randomized study

 

Group Var-HSA (N = 615)

Group Var + HSA (N = 616)

Mean age at first vaccination (SD), months

16.7 (3.3)

16.9 (3.4)

Female, n (%)

318 (51.7)

312 (50.6)

Country of enrolment, n (%)

 Estonia

82 (13.3)

82 (13.3)

 Germany

119 (19.3)

118 (19.2)

 Mexico

71 (11.5)

71 (11.5)

 Thailand

133 (21.6)

132 (21.4)

 United Kingdom

210 (34.1)

213 (34.6)

Geographic ancestry, n (%)

 African/ African American heritage

3 (0.5)

1 (0.2)

 Asian-Central South Asian heritage

2 (0.3)

2 (0.3)

 Asian-East Asian heritage

3 (0.5)

2 (0.3)

 Asian-South East Asian heritage

133 (21.6)

135 (21.9)

 White-Caucasian/European heritage

379 (61.6)

381 (61.9)

 Other

95 (15.5)

95 (15.4)

Ethnicity, n (%)

 Hispanic or Latino

75 (12.2)

73 (11.9)

 Not Hispanic or Latino

540 (87.8)

543 (88.1)

  1. Group Var-HSA, participants receiving varicella vaccine produced without HSA (human albumin serum); Group Var + HSA, participants receiving varicella vaccine containing HSA; N number of participants in each group, SD standard deviation; n (%), number (percentage) of participants in each category